ERBB2 and esophageal squamous cell carcinoma: Nig et al. found that the HER2 overexpression (3+) and HER2 equivocal expression (2+) rates were 1.5 and 5.9% in 68 ESCC patients, respectively, but they used TMA for evaluation [11].